Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,General Medicine
Reference17 articles.
1. Darnese MD, Griffith RI, Gleeson ML, et al. Second-line therapy in diffuse large B-cell lymphoma. Treatment patterns after outcome in older patients received outpatient chemotherapy. Leuk Lymphoma. 2017;58:1094–104.
2. Strauss DJ, Hamlin PA, Matasar MJ, et al. Phase I–II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment in elderly patients with relapsed or refractory diffuse large B-cell lymphoma no eligible for autologous stem cell transplantation. Br J Haematol. 2015;168:663–70.
3. Varlana SA, Sauter CS, Matasar MJ, et al. Outcome of primary refractory DLBCL treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2017;176:591–9.
4. Aviles A, Diaz-Maqueo JC, Torras V. Tratamiento de linfomas malignos refractarios con cisplatino, vinblastina y bleomicina. Rev Invest Clin. 1990;42:99–102.
5. Aviles A, Garcia EL, Guzman R, Talavera A, Poot JJ, Diaz-Maqueo JC. Estudio comparativo de dosis altas versus dosis convecionales de arabinoside de citosina en combinación con cisplatino y dexametasona en pacientes con linfoma refractario. Rev Invest Clin. 1992;43:146–50.